| Literature DB >> 25288678 |
Jessica M A Blair1, Helen E Smith1, Vito Ricci1, Amelia J Lawler1, Louisa J Thompson1, Laura J V Piddock2.
Abstract
OBJECTIVES: Enterobacteriaceae have multiple efflux pumps that confer intrinsic resistance to antibiotics. AcrB mediates clinically relevant multidrug resistance and is required for virulence and biofilm formation, making it an attractive target for the design of inhibitors. The aim of this study was to assess the viability of single transporters as a target for efflux inhibition using Salmonella Typhimurium as the model pathogen.Entities:
Keywords: AcrB; AcrD; AcrF; redundancy
Mesh:
Substances:
Year: 2014 PMID: 25288678 PMCID: PMC4291234 DOI: 10.1093/jac/dku380
Source DB: PubMed Journal: J Antimicrob Chemother ISSN: 0305-7453 Impact factor: 5.790
Percentage nucleotide identity and amino acid similarity between the RND efflux pump genes and proteins of Salmonella
| — | 70/79.1 | 74/90.4 | 55/46.7 | 55/48.6 | 59/63.4 | |
| — | — | 68/78.2 | 54/49.1 | 54/48.8 | 59/61.3 | |
| — | — | — | 54/47.4 | 53/48.5 | 57/63.1 | |
| — | — | — | — | 62/66.0 | 56/49.0 | |
| — | — | — | — | — | 56/49.2 | |
| — | — | — | — | — | — |
Expression of RND efflux pump genes and their regulators, quantified by real-time RT–PCR
| Strain | Fold change in gene expression | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RND efflux pump genes | known regulators of efflux | |||||||||||
| SL1344 | WT | 1.0 | 1.00 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| L644 | Δ | — | 1.0 | 1.4 | 1.2 | |||||||
| L132 | — | 1.0 | 0.9 | 1.2 | 0.8 | 1.4 | 1.3 | 0.3 | 0.6 | |||
| L131 | — | 0.9 | 1.0 | 1.3 | 1.4 | 0.9 | 1.5 | |||||
| L646 | Δ | — | — | 1.6 | 1.2 | 0.4 | 0.8 | |||||
| L1297 | Δ | — | — | 1.2 | 1.4 | 1.1 | 1.8 | 2.2 | 1.2 | |||
| L1395 | — | — | 1.0 | 1.3 | 1.4 | 0.4 | 1.0 | |||||
| L1405 | Δ | — | — | — | 1.1 | 1.6 | 1.9 | 1.0 | 0.5 | |||
Bold font indicates statistically significant (P ≤ 0.05) increased expression. Italic font indicates statistically significant (P ≤ 0.05) decreased expression.
Figure 1.Growth of efflux pump mutants in the presence of AcrB substrates. Growth of the efflux pump mutants in the presence of (a) ciprofloxacin and (b) doxycycline at a concentration of 0.25× the MIC for the WT. The data presented are the means of three biological replicates.
MICs of antimicrobials for SL1344 and its mutants
| Genotype | MIC (mg/L) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | CHL | CIP | TET | NAL | EtBr | FUS | AMK | GENT | HYG | STR | TOB | PABN | CCCP | ||
| SL1344 | WT | 2 | 4 | 0.015 | 1 | 4 | >256 | >256 | 4 | 0.5 | 32 | 8 | 2 | >1024 | 64 |
| L110 | <0.008 | 0.5 | 4 | 1 | 32 | 8 | 1 | 32 | |||||||
| L644 | Δ | <0.008 | 0.5 | 4 | 1 | 32 | 8 | 1 | 32 | ||||||
| L131 | 2 | 4 | 0.015 | 2 | 4 | >256 | >256 | 4 | 1 | 32 | 16 | 2 | >1024 | 64 | |
| L132 | 2 | 4 | 0.015 | 1 | 4 | >256 | >256 | 4 | 1 | 32 | 16 | 2 | >1024 | 64 | |
| L646 | Δ | 2 | <0.008 | 1 | 8 | 64 | 4 | 32 | |||||||
| L1297 | Δ | <0.008 | 0.5 | 2 | 0.5 | 32 | 8 | 1 | 32 | ||||||
| L1395 | 2 | 16 | 0.015 | 2 | 4 | >256 | >256 | 4 | 1 | 64 | 16 | 2 | >1024 | 64 | |
| L1405 | Δ | <0.008 | 0.5 | 64 | 32 | ||||||||||
AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; TET, tetracycline; NAL, nalidixic acid; EtBr, ethidium bromide; FUS, fusidic acid; AMK, amikacin; GEN, gentamicin; HYG, hygromycin; STR, streptomycin; TOB, tobramycin.
The aph gene used is aph(3′)-1, which provides resistance to kanamycin, neomycin and paromomycin.
Bold font indicates an increase in the MIC of the same compound compared with SL1344. Italic font indicates a decrease in the MIC of the same compound compared with SL1344.
Fold change in MIC compared with ΔacrB (L644)
| Genotype | AMP | CHL | CIP | TET | NAL | EtBr | FUS | AMK | GEN | HYG | STR | TOB | PABN | CCCP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L646 | Δ | ||||||||||||||
| L1297 | Δ | ||||||||||||||
| L1405 | Δ |
AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; TET, tetracycline; NAL, nalidixic acid; EtBr, ethidium bromide; FUS, fusidic acid; AMK, amikacin; GEN, gentamicin; HYG, hygromycin; STR, streptomycin; TOB, tobramycin.
The aph gene used is aph(3′)-1, which gives resistance to kanamycin, neomycin and paromomycin.
Bold font indicates an increase in MIC compared with the same compound for L644. Italic font indicates a decrease in the MIC of the same compound for ΔacrB. No value indicates no difference in MIC values.
Figure 2.Hoechst 33342 accumulation in single, double and triple efflux mutants. The data presented are the means of three separate experiments presented as fold changes compared with SL1344 at the endpoint of the assay (±SEM). Student's t-tests were performed to compare the accumulation of Hoechst 33342 by each strain with that of SL1344. Those returning P values of <0.05 are indicated by asterisks.
Figure 3.Accumulation of norfloxacin. The data shown are the means of three biological replicates (±SEM). Student's t-tests were performed to compare the accumulation of norfloxacin by each strain with that of SL1344. Those returning P values of <0.05 are indicated by asterisks.
Figure 4.Adhesion to (a) and invasion of (b) INT 407 cells in vitro by strains lacking AcrB, AcrD, AcrF and combinations of these. The data shown are the means of at least three independent experiments. Student's t-tests were used to compare the values for each strain with that of the WT, SL1344. P values of ≤0.05 were considered significant and are indicated by asterisks.